VEGFA and prostate carcinoma: For example, urinary elevations of fibrotic mediators (PAI-1, TIMP-1/2) and angiogenic factors (VEGF-A) observed in prostate cancer survivors with symptomatic RC suggest axes that could be trialed as both biomarkers and therapeutic targets.